Our website uses cookies in order to enhance your browsing experience. Refer to our privacy policy for more details. Please note that by using this site, you are consenting to the use of cookies. Internet Explorer is not supported. www.chugai-pharmabody.com works best on Chrome, Firefox, Edge and Safari.

Chugai Group | Contact Us | Sitemap
Contact

About

Chugai Group’s mission is to create innovative drugs for the benefit of patients.

Message from the CEO

Hideaki Shimada PH.D.

Director, Chief Executive Officer

In the global medical field, many diseases such as cancer, inflammatory diseases, and metabolic diseases still lack drug treatments or have existing drugs which do not sufficiently address the medical needs of patients. A subsidiary of Chugai Pharmaceutical, a member of the Roche group, Chugai Pharmabody Research (CPR) aims to pioneer new frontiers in drug discovery to solve these unmet needs.

Leveraging on our world-leading proprietary antibody engineering and cyclic peptide technology, we focus on innovative drug development that can move the needle and deliver better clinical outcomes for patients. These novel technologies enable us to expand druggable targets and invent unique therapeutic actions to meet unsatisfied clinical needs. Our cutting-edge technologies have allowed us to achieve a competitive advantage in the highly intensive field of drug discovery.

Tapping on Singapore’s holistic science ecosystem for world-class biomedical research, CPR is able to draw on Singapore’s strong infrastructure, a highly-trained pool of multinational scientists and supportive government policies to establish our highly-sophisticated antibody and cyclic peptide drug discovery platforms.

By working as a unified team and building upon our R&D investments, resources and talent, we have positioned ourselves as a global leader in antibody and cyclic peptic drug discovery research. We aspire to translate advanced science and technologies into revolutionary antibody and cyclic peptide drugs that can significantly improve patients’ lives and make a positive contribution to the global medical community.

OUR VISION

We aim to create innovative drug against the disease with high unmet medical needs for the human health around the world.

We will become a top innovator to realise advanced and sustainable patient-centric healthcare by our unique strength in science and technology with our highly diverse group of people having inclusive mind-set.

OUR MISSION

We create antibody drug clinical candidates using our proprietary antibody engineering technology platforms, and support drug development towards clinical development.

We identify biologically active cyclic peptide binders using our proprietary display technology platforms.

We develop innovative engineering technologies of proteins and cyclic peptides to create drugs even for difficult target molecules.

CORE VALUE

Patient Centric
Make each patient’s well-being our highest priority.

Pioneering Spirit
Pursue innovation by improving ourselves and thinking differently.

Integrity
Maintain the highest standards in all we do to create shared value with society.

Company Profile

Chugai Pharmabody Research (CPR) was established in Singapore as a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd. (“Chugai”), Japan’ s No.1 biopharmaceutical company, a member of Roche group, in January 2012 and started operations on July 2, 2012.

CPR conducts drug discovery research creating new antibody drug clinical candidates focusing on high value First-in-Class and Best-in-Class antibodies for a variety of targets and diseases using our proprietary antibody engineering technologies. CPR also conducts research utilizing our cyclic peptide drug discovery platform.

Company Name

Chugai Pharmabody Research Pte. Ltd.
(“Pharmabody” is coined from the words pharmaceutical and antibody.)

Establishment

January 10, 2012

Location

3 Biopolis Drive, #07–11 to 16 Synapse, Singapore 138623

Commencement of Operations

July 2, 2012

Capital

S$ 1.5 million

CEO

Hideaki Shimada Ph.D.

Shareholder

Wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd.

Board of Directors

Sir David Lane, Chairman of the Board

Hideaki Shimada, Director and CEO
Hitoshi Iikura, Director
Ashok Venkitaraman, Director

Target Headcount

155 employees

History

“”

1925

Juzo Ueno founded Chugai Shinkyaku Co., Ltd. and began the import and sale of medicinal drugs.

“”

1943

Reorganized into a corporation and company name changed to Chugai Pharmaceutical Co., Ltd. (Photo of Matsunage Plant)

“”

2002

Announcement of the strategic alliance with Roche and started business with Roche.

“”

2012

Established Chugai Pharmabody Research Pte. Ltd. In Singapore

“”

2018

Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd.

Sir David Lane

Chairman of the Board

With its proprietary antibody engineering and cyclic peptide research technologies, CPR has great potential to create a world-leading technology platform that transforms the efficacy of antibody and cyclic-based drugs. At the same time, CPR can leverage on this technology to contribute to a community of innovation. Since its establishment, CPR has increasingly embedded itself into Singapore’s vibrant research scene through its research performance and involvement in external activities such as the organisation of antibody symposiums. As a result, expectations from others have also been increasing. I am very proud to help CPR generate a pipeline of innovative products that will help patients around the world. I am also pleased to help CPR foster closer interactions with Singapore’s international research community.

Meet our Directors

DR HITOSHI IIKURA

Director

Since CPR’s founding more than a decade ago, we have achieved important milestones and delivered excellent results. Initially established to optimize antibodies and identify promising drug candidates, our innovative approach has led us to pioneer new technologies to improve the efficiency and efficacy of drug development.

We have expanded our scope of work to create new projects, especially in the research of antibodies and mid-size molecules. In particular, we are proud that our first made-in-Singapore drug, Crovalimab has recently been launched in Japan for the first time in the world. CPR has also made significant contributions to our mid-size molecule technology platform.

Going forward, we plan to expand our operations and create more hit compounds through display library techniques for antibody screening. By transforming CPR into a permanent overseas research hub of the Chugai Group, one of only two such research hubs, I believe that CPR will play a significant role in the development of innovative new drugs.